Base de dados : MEDLINE
Pesquisa : C10.228.140.546.399.750 [Categoria DeCS]
Referências encontradas : 21524 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 2153 ir para página                         

  1 / 21524 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29386181
[Au] Autor:Adelborg K; Szépligeti SK; Holland-Bill L; Ehrenstein V; Horváth-Puhó E; Henderson VW; Sørensen HT
[Ad] Endereço:Department of Clinical Epidemiology, Aarhus University Hospital, Denmark kade@clin.au.dk.
[Ti] Título:Migraine and risk of cardiovascular diseases: Danish population based matched cohort study.
[So] Source:BMJ;360:k96, 2018 01 31.
[Is] ISSN:1756-1833
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To examine the risks of myocardial infarction, stroke (ischaemic and haemorrhagic), peripheral artery disease, venous thromboembolism, atrial fibrillation or atrial flutter, and heart failure in patients with migraine and in a general population comparison cohort. DESIGN: Nationwide, population based cohort study. SETTING: All Danish hospitals and hospital outpatient clinics from 1995 to 2013. PARTICIPANTS: 51 032 patients with migraine and 510 320 people from the general population matched on age, sex, and calendar year. MAIN OUTCOME MEASURES: Comorbidity adjusted hazard ratios of cardiovascular outcomes based on Cox regression analysis. RESULTS: Higher absolute risks were observed among patients with incident migraine than in the general population across most outcomes and follow-up periods. After 19 years of follow-up, the cumulative incidences per 1000 people for the migraine cohort compared with the general population were 25 17 for myocardial infarction, 45 25 for ischaemic stroke, 11 6 for haemorrhagic stroke, 13 11 for peripheral artery disease, 27 18 for venous thromboembolism, 47 34 for atrial fibrillation or atrial flutter, and 19 18 for heart failure. Correspondingly, migraine was positively associated with myocardial infarction (adjusted hazard ratio 1.49, 95% confidence interval 1.36 to 1.64), ischaemic stroke (2.26, 2.11 to 2.41), and haemorrhagic stroke (1.94, 1.68 to 2.23), as well as venous thromboembolism (1.59, 1.45 to 1.74) and atrial fibrillation or atrial flutter (1.25, 1.16 to 1.36). No meaningful association was found with peripheral artery disease (adjusted hazard ratio 1.12, 0.96 to 1.30) or heart failure (1.04, 0.93 to 1.16). The associations, particularly for stroke outcomes, were stronger during the short term (0-1 years) after diagnosis than the long term (up to 19 years), in patients with aura than in those without aura, and in women than in men. In a subcohort of patients, the associations persisted after additional multivariable adjustment for body mass index and smoking. CONCLUSIONS: Migraine was associated with increased risks of myocardial infarction, ischaemic stroke, haemorrhagic stroke, venous thromboembolism, and atrial fibrillation or atrial flutter. Migraine may be an important risk factor for most cardiovascular diseases.
[Mh] Termos MeSH primário: Doenças Cardiovasculares/etiologia
Transtornos de Enxaqueca/complicações
Infarto do Miocárdio/etiologia
Acidente Vascular Cerebral/etiologia
[Mh] Termos MeSH secundário: Adulto
Fibrilação Atrial/epidemiologia
Fibrilação Atrial/etiologia
Índice de Massa Corporal
Doenças Cardiovasculares/epidemiologia
Estudos de Coortes
Comorbidade
Dinamarca/epidemiologia
Feminino
Insuficiência Cardíaca/epidemiologia
Insuficiência Cardíaca/etiologia
Seres Humanos
Incidência
Hemorragias Intracranianas/epidemiologia
Hemorragias Intracranianas/etiologia
Masculino
Meia-Idade
Transtornos de Enxaqueca/diagnóstico
Transtornos de Enxaqueca/epidemiologia
Infarto do Miocárdio/epidemiologia
Avaliação de Resultados (Cuidados de Saúde)
Doença Arterial Periférica/epidemiologia
Doença Arterial Periférica/etiologia
Estudos Prospectivos
Fatores de Risco
Fumar/epidemiologia
Acidente Vascular Cerebral/epidemiologia
Tromboembolia Venosa/epidemiologia
Tromboembolia Venosa/etiologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180202
[St] Status:MEDLINE
[do] DOI:10.1136/bmj.k96


  2 / 21524 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29469553
[Au] Autor:Goadsby PJ; Picard H; Mikol DD
[Ad] Endereço:King's College London, London, United Kingdom peter.goadsby@kcl.ac.uk
[Ti] Título:Preventive Therapies for Chronic Migraine.
[So] Source:N Engl J Med;378(8):774-5, 2018 02 22.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Bloqueadores dos Canais de Cálcio
Transtornos de Enxaqueca
[Mh] Termos MeSH secundário: Seres Humanos
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
0 (Calcium Channel Blockers)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180223
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMc1716990


  3 / 21524 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29469552
[Au] Autor:Balfagón G; Blanco-Rivero J; Márquez-Rodas I
[Ad] Endereço:Universidad Autónoma de Madrid, Madrid, Spain
[Ti] Título:Preventive Therapies for Chronic Migraine.
[So] Source:N Engl J Med;378(8):773-4, 2018 02 22.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Transtornos de Enxaqueca/prevenção & controle
[Mh] Termos MeSH secundário: Seres Humanos
[Pt] Tipo de publicação:LETTER; COMMENT
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180223
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMc1716990


  4 / 21524 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29466162
[Au] Autor:Silberstein SD; Yeung PP; Aycardi E
[Ad] Endereço:Thomas Jefferson University, Philadelphia, PA stephen.silberstein@jefferson.edu
[Ti] Título:Preventive Therapies for Chronic Migraine.
[So] Source:N Engl J Med;378(8):774, 2018 02 22.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Doença Crônica
Transtornos de Enxaqueca/prevenção & controle
[Mh] Termos MeSH secundário: Seres Humanos
[Pt] Tipo de publicação:LETTER; COMMENT
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180222
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMc1716990


  5 / 21524 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28467567
[Au] Autor:Çatav S; Alkaya Solmaz F; Kirdemir P
[Ti] Título:[The results of greater occipital nerve block applied for migraine headache].
[Ti] Título:Migren basagrisinda büyük oksipital sinir blogu uygulama sonuçlarimiz..
[So] Source:Agri;29(1):33-37, 2017 Jan.
[Is] ISSN:1300-0012
[Cp] País de publicação:Turkey
[La] Idioma:tur
[Ab] Resumo:OBJECTIVES: The aim of this study was to evaluate the efficacy of greater occipital nerve (GON) block in the treatment of migraine patients. METHODS: This study included 28 patients diagnosed with migraine between 2014 and 2015. The GON block procedure was applied by administering 1.5 ml of 2% lidocaine 2 cm lateral and 2 cm inferior to the external occipital protuberance. The patients were evaluated in respect of VAS scores, attack frequency, attack duration and the need for analgesia before the procedure. These parameters were evaluated again at 1 week, 1 month and 3 months after the procedure. RESULTS: The mean age of the patients was 42.21±10.13 years. The mean VAS score was 9.28±0.72 before the procedure and 2.96±2.16 at 1 week, 2.60±1.96 at 1 month and 1.75±1.37 at 3 months. The frequency of attacks was 9.42±4.51 before the procedure and, 5.42±3.30 at 1 month and 3.57±3.14 at 3 months. CONCLUSION: GON block with 1.5 ml of 2% lidocaine is a safe, simple and effective treatment method for migraine headache.
[Mh] Termos MeSH primário: Anestésicos Locais/administração & dosagem
Lidocaína/administração & dosagem
Transtornos de Enxaqueca/terapia
Bloqueio Nervoso
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Feminino
Seres Humanos
Masculino
Meia-Idade
Lobo Occipital
Medição da Dor
Índice de Gravidade de Doença
Resultado do Tratamento
Escala Visual Analógica
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anesthetics, Local); 98PI200987 (Lidocaine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.5505/agri.2016.57625


  6 / 21524 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28467565
[Au] Autor:Keskin Güler S; Güler S; Günes N; Çokal BG; Yön MI; Yoldas T
[Ad] Endereço:Department of Neurology, Ankara Training and Research Hospital, Ankara, Turkey. keskinselda@gmail.com.
[Ti] Título:[Validation of the revised illness perception questionnaire for migraine patients and the effects of earthquake experience on perception of disease].
[Ti] Título:Migren hastalarinda revize hastalik algisi ölçeginin geçerliligi ve deprem tecrübesinin hastalik algisi üzerine etkisi..
[So] Source:Agri;29(1):17-24, 2017 Jan.
[Is] ISSN:1300-0012
[Cp] País de publicação:Turkey
[La] Idioma:tur
[Ab] Resumo:OBJECTIVES: The aim of this study was to investigate the reliability of the Revised Illness Perception Questionnaire (IPQ) and to determine the effects of earthquake experience on the perception in migraine patients. METHODS: The sample was composed of 62 outpatients, consisting of with migraine diagnosis who were in Ercis during earthquake (n=33) and who had never had any earthquake experience (n=29).The interview form, IPQ-R and Beck Depression Scale (BDS) were applied. The study was carried out on migraine patients whose mean age was 31 and who had been diagnosed since 7.8 years. Comparison of groups with earthquake experience (group1) and without experience (group 2) there were no difference in point of demographic findings and disease severity (p>0.05). RESULTS: In the part concerning the manifestations of the disease, the most frequently manifestations were found pain, headache and fatige. The test was determined to be reliable. Illness coherence and timeline (cyclic) subscale scores (p<0.05) and BDS score (z: -2.006, p<0.05)were significantly higher in group 1. Although an earthquake caused an increase in depression scores did not cause much change in the IPQ-R scores. Group1 understand disease better and realize of the cyclical nature of the disease. Other perception parameters of the disease were same in both groups. CONCLUSION: A severe life event such as an earthquake did not much change IPQ-R scores in migraine patients. The results of this study demonstrated that IPQ could be used reliably in the Turkish migraine patients.
[Mh] Termos MeSH primário: Terremotos
Transtornos de Enxaqueca/psicologia
Psicometria
Estresse Psicológico
Inquéritos e Questionários
[Mh] Termos MeSH secundário: Adolescente
Adulto
Feminino
Seres Humanos
Masculino
Meia-Idade
Medição da Dor
Reprodutibilidade dos Testes
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; VALIDATION STUDIES
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.5505/agri.2016.88709


  7 / 21524 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29294327
[Au] Autor:Ren C; Liu J; Zhou J; Liang H; Wang Y; Sun Y; Ma B; Yin Y
[Ad] Endereço:Departments of Human Anatomy, Histology and Embryology, Peking University Health Science Center, Beijing 100191, China.
[Ti] Título:Low levels of serum serotonin and amino acids identified in migraine patients.
[So] Source:Biochem Biophys Res Commun;496(2):267-273, 2018 02 05.
[Is] ISSN:1090-2104
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Migraine is a highly disabling primary headache associated with a high socioeconomic burden and a generally high prevalence. The clinical management of migraine remains a challenge. This study was undertaken to identify potential serum biomarkers of migraine. Using Liquid Chromatography coupled to Mass Spectrometry (LC-MS), the metabolomic profile of migraine was compared with healthy individuals. Principal component analysis (PCA) and Orthogonal partial least squares-discriminant analysis (orthoPLS-DA) showed the metabolomic profile of migraine is distinguishable from controls. Volcano plot analysis identified 10 serum metabolites significantly decreased during migraine. One of these was serotonin, and the other 9 were amino acids. Pathway analysis and enrichment analysis showed tryptophan metabolism (serotonin metabolism), arginine and proline metabolism, and aminoacyl-tRNA biosynthesis are the three most prominently altered pathways in migraine. ROC curve analysis indicated Glycyl-l-proline, N-Methyl-dl-Alanine and l-Methionine are potential sensitive and specific biomarkers for migraine. Our results show Glycyl-l-proline, N-Methyl-dl-Alanine and l-Methionine may be as specific or more specific for migraine than serotonin which is the traditional biomarker of migraine. We propose that therapeutic manipulation of these metabolites or metabolic pathways may be helpful in the prevention and treatment of migraine.
[Mh] Termos MeSH primário: Alanina/análogos & derivados
Dipeptídeos/sangue
Metionina/sangue
Transtornos de Enxaqueca/diagnóstico
Serotonina/sangue
[Mh] Termos MeSH secundário: Adulto
Alanina/sangue
Arginina/sangue
Biomarcadores/sangue
Estudos de Casos e Controles
Cromatografia Líquida de Alta Pressão/métodos
Análise Discriminante
Feminino
Seres Humanos
Masculino
Metaboloma
Transtornos de Enxaqueca/sangue
Transtornos de Enxaqueca/fisiopatologia
Análise de Componente Principal
Prolina/sangue
Aminoacil-RNA de Transferência/sangue
Curva ROC
Triptofano/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Biomarkers); 0 (Dipeptides); 0 (RNA, Transfer, Amino Acyl); 333DO1RDJY (Serotonin); 600-21-5 (N-methylalanine); 704-15-4 (glycylproline); 8DUH1N11BX (Tryptophan); 94ZLA3W45F (Arginine); 9DLQ4CIU6V (Proline); AE28F7PNPL (Methionine); OF5P57N2ZX (Alanine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180103
[St] Status:MEDLINE


  8 / 21524 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29386182
[Au] Autor:Kurth T; Rohmann JL; Shapiro RE
[Ad] Endereço:Institute of Public Health, Charité - Universitätsmedizin Berlin, 10117 Berlin, Germany.
[Ti] Título:Migraine and risk of cardiovascular disease.
[So] Source:BMJ;360:k275, 2018 01 31.
[Is] ISSN:1756-1833
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Doenças Cardiovasculares
Transtornos de Enxaqueca
[Mh] Termos MeSH secundário: Seres Humanos
Fatores de Risco
[Pt] Tipo de publicação:EDITORIAL; COMMENT
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180212
[Lr] Data última revisão:
180212
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180202
[St] Status:MEDLINE
[do] DOI:10.1136/bmj.k275


  9 / 21524 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:29191325
[Au] Autor:Tobis JM; Charles A; Silberstein SD; Sorensen S; Maini B; Horwitz PA; Gurley JC
[Ad] Endereço:David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California. Electronic address: jtobis@mednet.ucla.edu.
[Ti] Título:Percutaneous Closure of Patent Foramen Ovale in Patients With Migraine: The PREMIUM Trial.
[So] Source:J Am Coll Cardiol;70(22):2766-2774, 2017 Dec 05.
[Is] ISSN:1558-3597
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Migraine is a prevalent and disabling disorder. Patent foramen ovale (PFO) has been associated with migraine, but its role in the disorder remains poorly understood. OBJECTIVES: This study examined the efficacy of percutaneous PFO closure as a therapy for migraine with or without aura. METHODS: The PREMIUM (Prospective, Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects With Migraine and PFO Using the AMPLATZER PFO Occluder to Medical Management) was a double-blind study investigating migraine characteristics over 1 year in subjects randomized to medical therapy with a sham procedure (right heart catheterization) versus medical therapy and PFO closure with the Amplatzer PFO Occluder device (St. Jude Medical, St. Paul, Minnesota). Subjects had 6 to 14 days of migraine per month, had failed at least 3 migraine preventive medications, and had significant right-to-left shunt defined by transcranial Doppler. Primary endpoints were responder rate defined as 50% reduction in migraine attacks and adverse events. Secondary endpoints included reduction in migraine days and efficacy in patients with versus without aura. RESULTS: Of 1,653 subjects consented, 230 were enrolled. There was no difference in responder rate in the PFO closure (45 of 117) versus control (33 of 103) groups. One serious adverse event (transient atrial fibrillation) occurred in 205 subjects who underwent PFO closure. Subjects in the PFO closure group had a significantly greater reduction in headache days (-3.4 vs. -2.0 days/month, p = 0.025). Complete migraine remission for 1 year occurred in 10 patients (8.5%) in the treatment group versus 1 (1%) in the control group (p = 0.01). CONCLUSIONS: PFO closure did not meet the primary endpoint of reduction in responder rate in patients with frequent migraine. (Prospective, Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects With Migraine and PFO Using the AMPLATZER PFO Occluder to Medical Management [PREMIUM]; NCT00355056).
[Mh] Termos MeSH primário: Cateterismo Cardíaco/métodos
Forame Oval Patente
Transtornos de Enxaqueca
Implante de Prótese
Dispositivo para Oclusão Septal
[Mh] Termos MeSH secundário: Adulto
Método Duplo-Cego
Ecocardiografia Doppler/métodos
Feminino
Forame Oval Patente/complicações
Forame Oval Patente/diagnóstico
Forame Oval Patente/cirurgia
Seres Humanos
Masculino
Meia-Idade
Transtornos de Enxaqueca/complicações
Transtornos de Enxaqueca/diagnóstico
Transtornos de Enxaqueca/fisiopatologia
Transtornos de Enxaqueca/terapia
Manejo da Dor/métodos
Medição da Dor/métodos
Implante de Prótese/efeitos adversos
Implante de Prótese/instrumentação
Implante de Prótese/métodos
Índice de Gravidade de Doença
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180207
[Lr] Data última revisão:
180207
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171202
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE


  10 / 21524 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27779368
[Au] Autor:Mekhail NA; Estemalik E; Azer G; Davis K; Tepper SJ
[Ad] Endereço:Pain Management Department, Cleveland Clinic, Cleveland, Ohio, U.S.A.
[Ti] Título:Safety and Efficacy of Occipital Nerves Stimulation for the Treatment of Chronic Migraines: Randomized, Double-blind, Controlled Single-center Experience.
[So] Source:Pain Pract;17(5):669-677, 2017 Jun.
[Is] ISSN:1533-2500
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: A recent multicenter study presented 52-week safety and efficacy results from an open-label extension of a randomized, sham-controlled trial for patients with chronic migraine (CM) undergoing peripheral nerve stimulation of the occipital nerves. We present the data from a single center of 20 patients enrolled at the Cleveland Clinic's Pain Management Department. METHODS: In this single center, 20 patients were implanted with a neurostimulation system, randomized to an active or control group for 12 weeks, and received open-label treatment for an additional 40 weeks. Outcomes collected included number of headache days, pain intensity, Migraine Disability Assessment (MIDAS), Zung Pain and Distress (PAD), direct patient reports of headache pain relief, quality of life, satisfaction, and adverse events (AEs). RESULTS: Headache days per month were reduced by 8.51 (±9.81) days (P < 0.0001). The proportion of patients who achieved a 30% and 50% reduction in headache days and/or pain intensity was 60% and 35%, respectively. MIDAS and Zung PAD were reduced for all patients. Fifteen (75%) of the 20 patients at the site reported at least one AE. A total of 20 AEs were reported from the site. CONCLUSION: Our results support the 12-month efficacy of 20 CM patients receiving peripheral nerve stimulation of the occipital nerves in this single-center trial.
[Mh] Termos MeSH primário: Terapia por Estimulação Elétrica/métodos
Transtornos de Enxaqueca/terapia
Manejo da Dor/métodos
[Mh] Termos MeSH secundário: Adulto
Método Duplo-Cego
Feminino
Seres Humanos
Masculino
Meia-Idade
Nervos Periféricos/fisiologia
Qualidade de Vida
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180123
[Lr] Data última revisão:
180123
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE
[do] DOI:10.1111/papr.12504



página 1 de 2153 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde